NICE Says Vertex Must ‘Engage Fully’ In UK Orkambi Negotiations
Health technology assessment body NICE says Vertex must engage “fully” with the institute so that it can complete its evaluations of the company’s CF drugs.
You may also be interested in...
Already dominant in cystic fibrosis, Vertex hopes its triple regimen will address roughly 90% of the patient population. It also hopes the benefits of the triple will smooth EU reimbursement talks.
The NHS in England says it has made a “revised and improved” offer to Vertex to make Orkambi available, but the company is not impressed and says its attitude to the negotiations has been mischaracterized.
Vertex has come under fire for its alleged extreme rigidity on pricing for its cystic fibrosis drug in England.